RoActemra

Selected form

Tocilizumab

Method of action: Immunosuppressive

Treatment option: Arthritis,Osteoarthritis, Temporal Arteritis, Rheumatoid Arthritis, Rheumatoid Factor

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of RoActemra

What is RoActemra?

RoActemra is a biological medicine that contains the active substance tocilizumab. It belongs to a group of medicines known as monoclonal antibodies. Unlike conventional chemical medications, biological medicines are produced using specialized processes involving living cells.

Mechanism of Action

The medication works by specifically targeting and blocking the activity of a protein called interleukin-6 (IL-6). In the body, IL-6 is a naturally occurring cytokine involved in the immune response. In certain conditions, the body produces excessive amounts of IL-6, which can lead to persistent inflammation and various symptoms associated with autoimmune and inflammatory disorders.

By binding to IL-6 receptors, RoActemra prevents the protein from triggering the inflammatory process. This action helps to reduce systemic inflammation and manage the underlying biological drivers of the condition being treated.

Therapeutic Use

RoActemra is used in the treatment of several different inflammatory conditions. These primarily include:

Rheumatoid Arthritis: A chronic condition where the immune system attacks the joints, causing pain, swelling, and stiffness.
Systemic Juvenile Idiopathic Arthritis (sJIA) and Polyarticular Juvenile Idiopathic Arthritis (pJIA): Inflammatory conditions affecting children.
Giant Cell Arteritis (GCA): A condition characterized by inflammation of the lining of the arteries, particularly those in the head.
Cytokine Release Syndrome (CRS): A severe systemic inflammatory response that can occur following certain types of specialized immunotherapy.

Depending on the specific condition, RoActemra may be used on its own or in combination with other medications, such as methotrexate.

Regulatory References

What side effects are possible with RoActemra?

Possible Side Effects and Safety Information

The safety profile of RoActemra (tocilizumab) is defined by officially documented adverse reactions classified by frequency and effect on specific body systems, as established in regulatory prescribing information. The medication's safety structure focuses on potential risks across several System-Organ Classes.

Frequency-Classified Adverse Reactions

Adverse events are categorized based on their documented incidence:

Very Common (affecting 1 in 10 or more): Infections of the upper respiratory tract.
Common (affecting up to 1 in 10): Headache, dizziness, hypertension, injection site reactions, elevated cholesterol (Hypercholesterolemia), and changes in blood counts (Leukopenia and Neutropenia). Elevated liver enzymes (ALT/AST) are also listed as common, highlighting potential effects on the Hepatobiliary System.
Uncommon (affecting up to 1 in 100): Serious hypersensitivity reactions, including anaphylaxis, and complications related to the Gastrointestinal System, such as gastrointestinal perforation.

Serious Adverse Reactions and Constraints

The regulatory label documents several clinically significant serious adverse reactions that require close observation. These include Serious and Fatal Infections (such as tuberculosis or severe bacterial infections) and Hepatotoxicity (severe liver injury, including acute liver failure).

Treatment initiation is restricted in patients with severe active infections or severe hepatic impairment. Furthermore, official safety guidance requires mandatory evaluation for latent tuberculosis infection prior to starting RoActemra, and the co-administration of live vaccines is restricted.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation states that there is limited clinical data available specifically concerning overdosage with the medicine Tocilizumab (RoActemra). Information about high-dose exposure is primarily based on clinical studies and isolated reports of accidental overdosage.

Documented Manifestations and Findings

In studies involving healthy volunteers who received high single doses, the most consistently documented physiological finding was dose-limiting neutropenia, a specific change in blood laboratory values. Furthermore, no serious adverse drug reactions were observed in these high-dose volunteer studies, and in one reported case of accidental overdosage in a patient who received 40 mg/kg, no adverse drug reactions were noted. Regulatory guidance also notes that doses exceeding 800 mg per infusion are generally not recommended.

Required Emergency Action

Due to the nature of the drug and the lack of a known specific antidote detailed in the prescribing information, the treatment of any suspected overdosage must consist of general supportive measures to address clinical signs and laboratory abnormalities that may occur. Immediate medical attention is required for proper assessment following any suspected overdose event. Patients or caregivers must contact the Poisons Information Centre or equivalent local emergency medical services for immediate advice and procedural guidance on management.

Therapeutic Uses of RoActemra

What RoActemra Treats: Main Uses and Benefits

RoActemra is commonly used to help with conditions characterized by periods of heightened symptoms related to systemic inflammation, specifically targeting several serious autoimmune diseases. The primary therapeutic areas include moderate to severe Rheumatoid Arthritis (RA), two forms of pediatric arthritis (Polyarticular and Systemic Juvenile Idiopathic Arthritis - PJIA and SJIA), Giant Cell Arteritis (GCA), and Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD). It is generally applied in contexts where additional symptomatic support is needed after other disease-modifying therapies have not worked well.

The medication helps address symptom clusters that may become intense or disruptive, such as chronic joint pain, stiffness, and severe constitutional fever. It is also relevant in clinical settings that involve acute or unstable symptom patterns, such as Cytokine Release Syndrome (CRS). This use is relevant when short-term symptomatic assistance is needed during phases when symptoms become more noticeable.

“The primary benefit is providing support that helps ease the overall symptom burden associated with chronic inflammation, which contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Relief for Inflammatory Symptoms

Category	Typical Symptom Relieved	Primary Benefit
Musculoskeletal	Joint stiffness and swelling	May assist with maintaining functional stability
Systemic	High, persistent fever	Supports the patient during difficult episodes by easing distress
Acute Crisis	Rapid inflammatory surges	Provides supportive relief when symptoms interfere with routine activities

Regulatory References

NIH MedlinePlus Drug Information on Tocilizumab Injection

Eligibility and Restrictions for Use

The eligibility profile for RoActemra (Tocilizumab) is defined by official regulatory documentation, focusing on patient status, age, and pre-treatment conditions.

Contraindications and Restrictions

Contraindicated Populations: The medicine is strictly contraindicated and must not be used in patients with a known hypersensitivity to Tocilizumab or any of its excipients. Use is also prohibited if the patient has an active, severe infection.

Condition-Specific Eligibility Rules: Non-eligibility is defined by specific laboratory thresholds. Treatment is typically not recommended if the patient has a severely low Absolute Neutrophil Count (ANC), a severely low platelet count, or baseline liver transaminases (ALT/AST) that are significantly elevated. Use in patients with severe renal or hepatic impairment is often restricted or considered not recommended due to insufficient data.

Age and Reproductive Status

Age-related Eligibility Rules: RoActemra is approved for adults across all labeled indications. Pediatric use is restricted to children aged two years and older (in many regions) for specific forms of Juvenile Idiopathic Arthritis (JIA). For older adults, no specific age-related dosage adjustments are required.

Pregnancy and Lactation: Use is not recommended during pregnancy, and the medicine is contraindicated while breastfeeding, requiring a decision to discontinue the medicine or nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

RoActemra (tocilizumab) may affect the activity of certain liver enzymes responsible for metabolizing many other medicines. Its core interaction profile is primarily defined by its effects on the Cytochrome P450 (CYP450) enzyme system.

Key Interaction Domains

Interaction Type	Interacting Products/Classes	Regulatory Constraint/Requirement
Pharmacokinetic (CYP450 Substrates)	Medicines metabolized by CYP3A4, CYP1A2, or CYP2C9, especially those with a narrow therapeutic index (e.g., simvastatin).	The metabolism of these medicines may be altered when RoActemra treatment is started or stopped, potentially requiring close monitoring and dose adjustment by a healthcare professional.
Pharmacodynamic (Biologic Agents)	Other Biologic Agents that suppress the immune system.	Concurrent use with other biologics is not recommended due to the potential for increased immunosuppression and risk of serious infection.
Additive Risk (Hepatotoxic Drugs)	Potentially hepatotoxic drugs (e.g., methotrexate)	Co-administration may increase the frequency and severity of liver enzyme elevations, mandating routine monitoring of liver function tests.
Vaccines	Live Vaccines	Co-administration is not recommended as the safety and effectiveness of the vaccine may be compromised.

These official regulatory domains establish that the initiation or discontinuation of RoActemra necessitates a review of all concurrently used medicines, particularly those with a narrow therapeutic index, to prevent a loss of therapeutic effect or an increase in toxicity.

Mechanism of Action

How RoActemra Works

RoActemra (tocilizumab) is a monoclonal antibody that acts as a highly selective antagonist of the Interleukin-6 (IL-6) receptor. Its primary mechanism involves binding to both membrane-bound and soluble forms of the IL-6 receptor, physically blocking the attachment of the IL-6 protein.

This specific receptor blockade interrupts the intracellular JAK/STAT signaling pathway that is typically initiated by IL-6, thereby inhibiting downstream cellular activation. The interruption of this cascade suppresses the genetic instructions for the synthesis of acute-phase proteins, which are key systemic inflammatory mediators. Consequently, the mechanism regulates the acute-phase response, resulting in the reduction of circulating markers like C-reactive protein (CRP) and modulating the physiological processes driven by excessive IL-6 signaling.

Dosage and Administration Information

RoActemra is administered through one of two official routes: intravenous (IV) infusion or subcutaneous (SC) injection. The medicine is formulated as a concentrate for IV infusion (20 mg/mL) or a 162 mg/0.9 mL solution for SC injection in a pre-filled syringe or autoinjector.

Administration and Dosing Principles

The dosing schedule is highly specialized and is determined by the patient’s specific condition and body weight. The IV formulation must be professionally diluted in a sodium chloride solution and administered as a single infusion over 60 minutes. The SC injection must be allowed to reach room temperature before use.

For adult Rheumatoid Arthritis, the IV dose typically begins at 4 mg/kg every four weeks and may be increased to 8 mg/kg based on response, not exceeding 800 mg per infusion. The SC dose of 162 mg is administered either every other week (q2w) or weekly (qw), depending on the patient's body weight, with weekly use being standard for patients ≥ 100 kg.

Pediatric dosing is weight-based (mg/kg for IV) with intervals of two or four weeks, based on the specific indication. A change in dose should only be based on a consistent change in body weight over time. When patients transition from IV to SC therapy, the first SC dose is administered at the time the next scheduled IV dose was due. No routine dose adjustment is specified for older adults (≥ 65 years).

Dose adjustments or interruption of the regimen (e.g., reducing frequency or dose amount) is a formal procedural instruction outlined in official labeling for managing certain dose-related changes during the course of treatment.

Recent Clinical Evidence

Research Evidence Overview: RoActemra (Tocilizumab)

Evidence for Use in Rheumatoid Arthritis (RA) and Giant Cell Arteritis (GCA)

The research for moderate to severe Rheumatoid Arthritis (RA) was studied for adult patients using Randomized Controlled Trials (RCTs) and various other study designs, including long-term data collection. These studies explored how outcomes related to physical functioning and measures of disease activity changed over time in patients whose condition had not responded sufficiently to prior therapies. Researchers monitored common measures of disease activity and examined the progression of structural joint damage. Findings describe patterns observed in the studies related to changes in these scores and patterns in radiographic outcomes over the observation period. Long-term outcomes are not fully established beyond the observation period of the initial trials, and comparative evidence examining all treatment scenarios is limited.

For Giant Cell Arteritis (GCA), the research was evaluated in adult participants, typically over the age of 50, using RCTs designed to study its use alongside a standardized reduction of steroid medication. Studies examined the proportion of patients who could maintain disease control while the steroid dosage was lowered. Research reports measurements related to the cumulative amount of steroid administered during the study period. Follow-up durations were limited, and limited information exists for long-term outcomes regarding subsequent relapse rates or associated vascular events.

Evidence for Use in Pediatric and Other Autoimmune Conditions

In Systemic and Polyarticular Juvenile Idiopathic Arthritis (SJIA/PJIA), conditions characterized by fluctuating manifestations, research was studied for the pediatric population aged two years and older. Studies explored specialized pediatric outcome metrics and the resolution of systemic features (e.g., fever) in SJIA. Studies report patterns of change in disease activity in the observed populations. A limitation is that sample sizes were modest.

For Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), research examined changes in lung function using Forced Vital Capacity (FVC) as the primary measure in controlled trials. Research highlights changes measured in the rate of FVC decline during the study interval. These studies contribute to the broader evidence landscape regarding SSc-ILD.

What Remains Uncertain in the Research

The research overall contributes to understanding symptom patterns, but several gaps exist. Long-term effects are not fully established for many chronic conditions because follow-up durations were limited in the most controlled trials. For rare diseases, sample sizes were modest. This means the results apply only to the populations studied and generalizability is less clear. Finally, comparative evidence is lacking in some areas. This section provides context about the existing evidence and highlights the areas where research is ongoing and additional information is needed.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about RoActemra (FAQ)

Q: Is RoActemra the same type of medicine as Humira or Enbrel?

RoActemra is classified as a biologic medicine, specifically an Interleukin-6 (IL-6) receptor antagonist (tocilizumab). According to official documents, it works by blocking the IL-6 protein to reduce inflammation. Other common biologics, such as Humira or Enbrel, target a different inflammatory messenger called Tumor Necrosis Factor (TNF). This means while they are all biologics, they utilize different pathways to achieve their purpose.

Q: What is the main difference between an IV infusion of RoActemra and a subcutaneous injection?

The primary difference is the administration route and frequency. The intravenous (IV) formulation is typically given every four weeks and must be administered by a healthcare professional in a clinic setting. In contrast, the subcutaneous (SC) injection is administered weekly or every other week, depending on the patient's specific condition and weight. The SC form is generally intended for administration by the patient or caregiver, following proper training.

Q: Can RoActemra affect my ability to get pregnant?

Official prescribing information states that RoActemra is generally not recommended during pregnancy due to insufficient human data. Animal studies indicated potential risks to the developing fetus. For breastfeeding, regulatory guidelines state that a decision must be made to either discontinue the medicine or stop nursing. Consultation with a healthcare provider is necessary when considering treatment initiation or continuation while planning pregnancy.

Q: Is it common to feel tired after a RoActemra infusion?

While fatigue is not specifically listed as a common, standalone side effect in official frequency tables, it may sometimes be reported as a symptom of an infection. Infections of the upper respiratory tract are classified as a very common adverse reaction with this medicine. Any patient experiencing unusual or severe tiredness should consult their prescribing healthcare provider.

Q: What kind of routine blood tests are needed while taking RoActemra?

Official guidelines require periodic blood tests to monitor several factors while taking this medicine. This monitoring includes checking blood counts, such as the Absolute Neutrophil Count and platelet count, to ensure they remain within an acceptable range. Liver function tests and lipid parameters, such as cholesterol, are also routinely monitored.

Q: Is RoActemra considered a chemotherapy drug?

RoActemra is classified as a biologic agent, specifically a monoclonal antibody. This type of medicine works by selectively targeting the Interleukin-6 (IL-6) receptor, a specific messenger protein. It is not classified as a conventional cytotoxic chemotherapy drug, which generally works by killing quickly dividing cells.

Q: What does the term 'biologic' mean when referring to RoActemra?

The term 'biologic' refers to a medicine that is derived from living organisms, such as proteins or cells. RoActemra is a specific type of biologic classified as a recombinant humanized monoclonal antibody. This advanced manufacturing process allows the medicine to highly selectively target the body's inflammatory process.

Q: Can people with diabetes use RoActemra?

Official documents indicate that patients with conditions that increase the risk of infection, such as diabetes, should be monitored closely while taking this medicine. This is because these underlying conditions may contribute to an increased risk of serious infections. Final eligibility for this medicine is determined based on a comprehensive assessment by a healthcare provider.

Q: What are the most commonly reported serious side effects of RoActemra in research studies?

Studies indicate that the most commonly reported serious adverse reactions are related to serious infections. Examples include pneumonia, urinary tract infections, cellulitis, and sepsis. The official product label contains a boxed warning highlighting the risk of serious infections.

Q: Are there any known interactions between RoActemra and common vaccines?

Regulatory information states that live vaccines are not recommended for use while taking RoActemra. For inactivated or non-live vaccines, the medicine may impair the body's immune response. This means the vaccine might be less effective than usual in protecting against the disease.

Q: Does RoActemra work for joint stiffness, joint pain, or both?

RoActemra is indicated for inflammatory conditions that present with both joint pain and stiffness, among other signs and symptoms. Clinical studies have shown that the medicine improves objective measures of physical function and disease activity. Its general purpose is to reduce chronic, systemic inflammation throughout the body.

Q: Can taking RoActemra affect the results of a regular flu shot?

Yes, regulatory documents indicate that RoActemra can affect the immune system's response to vaccinations. This means that a non-live vaccine, such as the regular seasonal flu shot, may be less effective in creating protective immunity. Consultation with the healthcare team regarding any planned vaccinations is recommended.

Q: What should a patient do if they notice signs of an infection while on RoActemra?

Patients should be closely monitored for any signs or symptoms of infection, which can sometimes be subtle. Regulatory guidance states that if a serious infection develops, the medicine should be interrupted until the infection is brought under control. Patients should seek immediate medical attention if they suspect they have an infection.

Q: Can RoActemra be used by people with a history of heart problems?

Studies examining cardiovascular safety found that the rate of myocardial infarction (heart attack) in patients taking RoActemra was comparable to the rate observed in patients taking a placebo. Final eligibility for this medicine is determined based on a comprehensive assessment by a healthcare provider, taking into account the full medical history.

Q: Does RoActemra have a 'Black Box Warning' in the U.S. regulatory information?

Yes, the U.S. Prescribing Information for RoActemra contains a BOXED WARNING, commonly referred to as a Black Box Warning. This warning highlights the risk of Serious Infections that have been observed in patients taking the medicine. This is a standard way for regulators to emphasize important safety information.

Q: Can RoActemra be used in combination with methotrexate?

Yes, RoActemra is often used in combination with medicines like methotrexate. Because both medicines can affect the liver, this combination requires close monitoring of liver function tests. Official regulatory documents emphasize that monitoring of liver enzymes is mandated when these medicines are used together.

Q: What is the risk of certain cancers mentioned in the research data for RoActemra?

Official information states that RoActemra may increase the risk of certain cancers by changing the way the immune system functions. Malignancies, or cancers, were observed in clinical studies. Concerns regarding this potential risk should be discussed with a healthcare provider.

Q: Is RoActemra available as a generic version?

RoActemra, whose active ingredient is tocilizumab, is a biologic medicine. As such, it does not have a traditional generic version but rather biosimilar versions. Several biosimilars of tocilizumab have been authorized for use by regulatory bodies in the United States and the European Union.

Q: Does RoActemra only treat symptoms, or does it change the course of the disease?

Regulatory-cited clinical studies for rheumatoid arthritis demonstrated that RoActemra does more than just address symptoms. The evidence indicates that the medicine has been shown to inhibit the progression of structural joint damage in adults. It is also shown to improve objective measures of physical function and disease activity.

Q: What kind of side effects are common with the first few doses of RoActemra?

The official labeling notes that certain events can occur within 24 hours of an infusion, which may be noticeable after the first few doses. These reactions can include symptoms like rash, headache, diarrhea, hives (urticaria), and stomach discomfort. Any patient experiencing severe symptoms should seek medical attention.

Q: How is RoActemra different from traditional disease-modifying antirheumatic drugs (DMARDs)?

RoActemra is a biologic medicine with a highly specific mechanism of action. It works by selectively blocking the Interleukin-6 (IL-6) receptor, a specific messenger protein. Traditional, non-biologic disease-modifying antirheumatic drugs (DMARDs) typically have a broader, less targeted effect on the immune system.

Q: What does 'contraindication' mean in the context of RoActemra use?

The term 'contraindication' is a serious regulatory term meaning that the medicine must not be used under certain circumstances. For RoActemra, contraindications include a known hypersensitivity to the drug or any of its components. It is also contraindicated if a patient has an active, severe infection.

Q: Can RoActemra cause skin reactions or rashes?

Yes, the official product information lists that skin reactions have been reported. This includes common injection site reactions, such as pain or redness, particularly with the subcutaneous form. Serious hypersensitivity reactions, which can involve a rash or other severe skin changes, have also been reported rarely.

Q: What are the official recommendations about consuming alcohol while taking RoActemra?

Official documents do not specify a general restriction on consuming alcohol while taking RoActemra. However, the medicine requires monitoring of liver enzyme levels due to the risk of hepatotoxicity (liver damage). The potential impact of alcohol consumption should be reviewed with a healthcare provider, particularly if taking other medications that affect the liver.

Q: What are the potential risks of taking RoActemra during pregnancy?

The potential risks are not fully understood due to insufficient human data. Animal studies, however, showed potential risks to the developing fetus. Official regulatory guidance states that the medicine should only be used during pregnancy if the potential benefits are determined to outweigh the potential risks to the fetus.

Q: What should I know about diverticulitis and RoActemra?

Official safety information advises using RoActemra with caution in patients who have a history of diverticulitis or are at risk for gastrointestinal perforation (a tear in the wall of the stomach or intestines). Events of gastrointestinal perforation, primarily as complications of diverticulitis, have been reported in clinical trials.

How should RoActemra be stored and disposed of?

Storage and Disposal of RoActemra (Tocilizumab)

Storage Requirements	Details
Temperature	Store in a refrigerator at 2 C to 8 C (36 F to 46 F). Do not freeze.
Protection	Keep the product in the original carton to protect it from light and moisture.
Stability	Subcutaneous products may be kept out of the refrigerator for up to 14 days at or below 30 C (86 F). Do not return it to the refrigerator after this time.
Handling	Allow the syringe/autoinjector to warm naturally for about 30 minutes before use. Do not shake.
Child Safety	Keep all RoActemra products and used sharps containers out of the reach and sight of children.

Disposal Instructions

Used needles and syringes must be placed immediately into an FDA-cleared sharps disposal container. Do not re-cap the needle or throw loose items into household trash. The full sharps container must be disposed of according to local community guidelines and laws for medical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.